New analyses and commercial moves are reshaping how GLP‑1 medicines reach patients: a health‑economics review found potency and outcomes justify higher prices for weight‑loss GLP‑1s under some models, while Eli Lilly struck a distribution tie‑up with Walmart to expand patient access to its obesity drug Zepbound through in‑store pharmacy pickup for online orders. Together, the data and partnerships show manufacturers balancing price, volume and novel access channels. Payers, retailers and manufacturers are testing hybrid go‑to‑market plays—direct consumer channels, retail pharmacy integration and value‑based pricing models—to manage cost and access. For health systems and employers, the combination of demonstrated clinical benefit and distribution scale will drive negotiations over coverage and copay structures. Expect more retail and DTC partnerships as companies seek to preserve market share while navigating payer pressure and public debate about long‑term affordability.